Cargando…

Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults

BACKGROUND: Ubrogepant is a novel, oral calcitonin gene–related peptide (CGRP) receptor antagonist in development for the acute treatment of migraine. This trial evaluated the safety and tolerability of ubrogepant, focusing on hepatic safety, when administered intermittently with high-frequency dosi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goadsby, Peter J, Tepper, Stewart J, Watkins, Paul B, Ayele, Girma, Miceli, Rosa, Butler, Matthew, Severt, Lawrence, Finnegan, Michelle, Szegedi, Armin, Trugman, Joel M, Jakate, Abhijeet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900570/ https://www.ncbi.nlm.nih.gov/pubmed/31537107 http://dx.doi.org/10.1177/0333102419869918

Ejemplares similares

Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications
por: Goadsby, Peter J, et al.
Publicado: (2020)

Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis
por: Blumenfeld, Andrew M., et al.
Publicado: (2021)

Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans
por: Jakate, Abhijeet, et al.
Publicado: (2020)

Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial
por: Ailani, Jessica, et al.
Publicado: (2020)

Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain
por: Lipton, Richard B., et al.
Publicado: (2022)

Single Therapeutic and Supratherapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized Trial
por: Jakate, Abhijeet, et al.
Publicado: (2019)

Mechanistic Investigations Support Liver Safety of Ubrogepant
por: Smith, Brenda, et al.
Publicado: (2020)

Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial
por: Ashina, Messoud, et al.
Publicado: (2023)

Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials
por: Blumenfeld, Andrew M., et al.
Publicado: (2021)

Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males
por: Ankrom, Wendy, et al.
Publicado: (2020)

Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials
por: Hutchinson, Susan, et al.
Publicado: (2021)

Ubrogepant: First Approval
por: Scott, Lesley J.
Publicado: (2020)

Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug–drug interaction study
por: Jakate, Abhijeet, et al.
Publicado: (2021)

Correction to: Ubrogepant: First Approval
por: Scott, Lesley J.
Publicado: (2020)

A Comprehensive Review of the Mechanism, Efficacy, Safety, and Tolerability of Ubrogepant in the Treatment of Migraine
por: Dighriri, Ibrahim M, et al.
Publicado: (2023)

Ubrogepant to Treat Acute Migraine in Adults
por: Edinoff, Amber N., et al.
Publicado: (2021)

Ubrogepant in the Acute Management of Migraine: A Narrative Review
por: Chiang, Chia-Chun, et al.
Publicado: (2021)

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine
por: Franklin, Meg, et al.
Publicado: (2020)

Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial
por: Schwedt, Todd J, et al.
Publicado: (2021)

Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial
por: Lipton, Richard B., et al.
Publicado: (2022)

Ubrogepant, an Acute Treatment for Migraine, Improved Patient‐Reported Functional Disability and Satisfaction in 2 Single‐Attack Phase 3 Randomized Trials, ACHIEVE I and II
por: Dodick, David W., et al.
Publicado: (2020)

Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache
por: Navratilova, Edita, et al.
Publicado: (2020)

Single‐Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial
por: Boinpally, Ramesh, et al.
Publicado: (2021)

Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: A meta-analysis
por: Zhang, Zizhen, et al.
Publicado: (2021)

Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings
por: Polavieja, Pepa, et al.
Publicado: (2022)

Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers
por: Jakate, Abhijeet, et al.
Publicado: (2019)

Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm
por: Johnston, Karissa M, et al.
Publicado: (2022)

Single‐Dose Pharmacokinetics and Safety of Ubrogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial
por: Boinpally, Ramesh, et al.
Publicado: (2022)

Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study
por: Manack Adams, Aubrey, et al.
Publicado: (2023)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Tolerability, and Safety of Celecoxib Oral Solution (ELYXYB) in Acute Treatment of Episodic Migraine with or without Aura
por: Lipton, Richard B, et al.
Publicado: (2021)

Superior efficacy of St John's wort extract WS(® )5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]
por: Kasper, Siegfried, et al.
Publicado: (2006)

Asenapine pharmacokinetics and tolerability in a pediatric population
por: Dogterom, Peter, et al.
Publicado: (2018)

Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder
por: Gao, Keming, et al.
Publicado: (2013)

Efficacy, Tolerability, and Safety of DFN‐15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Study
por: Lipton, Richard B., et al.
Publicado: (2019)

Similar pharmacokinetics of three dosing regimens comprising two oral delayed‐release mesalamine formulations in healthy adult volunteers: Randomised, open‐label, parallel‐group study
por: Vande Casteele, Niels, et al.
Publicado: (2020)

Making Better Dose Decisions: Using Exposure‐Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment
por: Li, Chi‐Chung, et al.
Publicado: (2020)

Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data
por: Giles, Thomas D., et al.
Publicado: (2017)

Pathophysiology and Treatment of Alien Hand Syndrome
por: Sarva, Harini, et al.
Publicado: (2014)

Safety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia
por: Cazorla, Pilar, et al.
Publicado: (2012)

Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials
por: Lipton, Richard B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8stuvcv68hs6b6fsn5oa0o6hbp